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Editorial summary:  Rat or human lung samples are enzymatically digested 
and CD31 expressing cells positively selected using magnetic-activated cell 
sorting prior to plating in endothelial-specific growth conditions. 
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Abstract 
Blood vessels are crucial for the normal development, lifelong repair and homeostasis of tissues. 
Recently, vascular progenitor cell-driven “postnatal vasculogenesis” has been suggested as an 
important mechanism contributing to new blood vessel formation and organ repair. Among 
several described progenitor cell types contributing to blood vessel formation, endothelial colony 
forming cells (ECFCs) have received widespread attention as lineage-specific 'true' vascular 
progenitors. Herein, we describe a protocol for the isolation of pulmonary microvascular ECFCs 
from human and rat lung tissue. Our technique takes advantage of an earlier protocol for 
isolating circulating ECFCs from the mononuclear cellular fraction of peripheral blood.  We 
adapted the earlier protocol to isolate resident ECFCs from the distal lung tissue. Following 
enzymatic dispersion of rat or human lung samples into a cellular suspension, CD31 expressing 
cells are positively selected using magnetic-activated cell sorting (MACS) and plated in 
endothelial-specific growth conditions. The colonies arising after 1-2 weeks in culture are 
carefully separated and expanded to yield pure ECFC cultures after a further 2-3 weeks. The 
resulting cells demonstrate the defining characteristics of ECFCs such as: (i) 'cobblestone' 
morphology of cultured cell monolayers; (ii) acetylated low-density lipoprotein uptake and Ulex 
lectin binding; (iii) tube-like network formation in Matrigel; (iv) expression of endothelial cell-
specific surface markers and the absence of hematopoietic/myeloid surface antigens; (v) self-
renewal potential displayed by the most proliferative cells; and (vi) contribution to de novo 
vessel formation in an in vivo murine implant model. Assuming typical initial cell adhesion and 
proliferation rates, the entire procedure can be completed within 4 weeks. Isolation and culture of 
lung vascular ECFCs will allow assessment of the functional state of these cells in experimental 
and human lung diseases, providing newer insights into their pathophysiological mechanisms. 
 
INTRODUCTION 
The role of vasculature in the development, lifelong repair and maintenance of the lung is 
unquestionably paramount. Chronic lung disease is predicted to become the third most common 
cause of death  by 20201. It has long been recognised that many lung ailments across lifespan, 
such as chronic lung disease of prematurity or emphysema in adults, display vascular 
abnormalities2-5. A better understanding of how the lung vasculature contributes to normal lung 
development and is impaired during disease is crucial to develop new therapeutic strategies for 
debilitating lung diseases5.  
Since the description of circulating endothelial progenitor cells (EPCs) by Asahara et al6, 
postnatal vasculogenesis has been purported as an important mechanism contributing to new 
blood vessel formation7,8. Extensive attempts were made to identify and more precisely 
characterize EPCs. More specifically, efforts have been made to correlate the number and 
function of EPCs with outcome in various diseases 9,10, including lung disorders 11,12. Among the 
various described cell types with an “EPC phenotype”, endothelial colony forming cells 
(ECFCs), also referred to as late-outgrowth EPCs, have received widespread attention as lineage-
specific 'true EPCs' participating in neovasculogenesis 10,13,14. ECFCs may reside throughout the 
vascular endothelium contributing to generalized vascular integrity15 .  ECFCs are mobilized into 
a circulating pool of endothelial progenitors, potentially involved in neovasculogenesis via tissue 
recruitment and homing16, however the mechanism for this is not known at present. ECFCs may 
also contribute to new vessel formation during lung organogenesis as well as support lifelong 
lung repair and maintenance. These characteristics may mean ECFCs are implicated in the 
disease processes of several childhood and adult lung diseases. Therefore, studying the 
functional characteristics of tissue resident ECFCs will widen our understanding of chronic lung 
diseases and may contribute to the development of more efficient treatments.  
Development of the protocol: 
A method for the isolation and culture of ECFCs from rat and human lung samples was 
established and standardized in our laboratory to study the survival capacity and other functional 
characteristics of pulmonary vascular ECFCs 17. This technique takes advantage of an earlier 
protocol for isolating circulating ECFCs from umbilical cord blood or peripheral blood 
mononuclear cells 18 and has been extensively revised and optimized for successful isolation of 
resident ECFCs from a solid organ such as the lung. A comprehensive overview of this method 
is provided in Figure 1. Following enzymatic dispersion of rat or human lung samples (Figure 
2), CD31 expressing cells are positively selected using magnetic-activated cell sorting (MACS) 
and plated in endothelial-specific growth conditions (Figure 3). The ECFC colonies that arise 
after 1-2 weeks in culture are carefully isolated and expanded to yield pure ECFC cultures. The 
phenotype of ECFCs is confirmed by (i) classical 'cobblestone' morphology of cultured cell 
monolayers, (ii) assessment of endothelial cell characteristics via acetylated low-density 
lipoprotein uptake and Ulex lectin binding, (iii) tube-like network formation in Matrigel, (iv) 
endothelial specific surface antigen expression, (v) self-renewal potential displayed by the most 
proliferative cells, and (vi) assessment of their ability to contribute to de novo vessel formation 
in an in vivo murine implant model 13.  
Comparison with existing methods: 
Recently, three papers have demonstrated the existence of endothelial progenitor-like cells with a 
high potential for proliferation in the peripheral microvasculature of rat 19,20 and mouse 21 lungs. 
The Stevens group isolated ECFC-like cells from peripheral rat lung tissue following collagenase 
digestion, plating and selection of late-outgrowth endothelial colonies19. The cells were cultured 
in DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics and observed to 
demonstrate ECFC-like phenotype, on the basis of both expression of surface antigens and 
functional behaviours such as uptake of low-density lipoprotein (LDL), maintenance of high 
barrier resistance, in vitro and in vivo vasculogenesis in Matrigel 20. Weich and colleagues21,22, 
on the other hand, selected out CD31+ cells from mouse peripheral lung microvasculature by 
successively using magnetic and fluorescence-activated cell sorting (MACS and FACS). They 
expanded these cells in DMEM enriched with 20% FBS and demonstrate their expression of 
panendothelial cell surface markers22 and ability to bind Griffonia simplicifolia lectin. Their cells 
were also negative for CD45, for CD117 (c-kit or SCF receptor) and CD41, which are markers 
for leukocytes and hematopoietic stem and progenitor cells. Using limiting dilution assays at 
single-cell seeding density, they show that at least 15% of those cells were capable of very high 
proliferation rate. These cells also generated blood vessels of donor origin in Matrigel plugs 
implanted subcutaneously in recipient mice. 
In a recent study, we combined CD31-positive selection and clonal ring isolation of endothelial 
colonies and expanded the derived cells to establish primary endothelial cell lines from rat and 
human peripheral lung vasculature17. These cells were assessed for surface marker expression 
and a panel of functional assays that defined them as ECFCs 13,18. In this article, in addition to 
providing a detailed step-by-step description of this technique, we also provide a troubleshooting 
guide for the routine issues that might arise during the isolation process. The focus of this 
protocol is to resident lung ECFCs and we have not compared lung and other organ ECFCs. 
Rafii et al23 used lectin staining to isolate human bone marrow microvascular cells and showed 
they displayed the same antigens as human umbilical vein endothelial cells (CD31, CD34, von 
Willebrand factor, and uptake of AcLDL). 
 
Applications of the method 
We have tested this protocol in adult human and rat lung samples17. It also allows isolation of 
ECFCs from developing rat and human lungs, i.e. lungs from newborn rats as early as 14-days of 
age or aborted human fetuses at 18-20 weeks gestation17. Isolation and culture of lung resident 
ECFCs from these samples allows functional assessment of these cells in experimental and 
clinical lung diseases. ECFCs isolated and expanded by this technique can also be used in 
therapeutic studies. In addition, the described protocol enables the isolation and culture of a 
properly defined subset of endothelial cells with demonstrable progenitor-like characteristics (i.e 
a population of ‘lineage-specific’ endothelial progenitor cells); this will enable an improved 
understanding of endothelial cell biology.  
Limitations 
The sensitivity of the current protocol to successfully isolate lung ECFCs is limited by the 
vascular density of the starting tissue that is being processed. The existing method probably 
requires capturing a threshold number of CD31+ cells for successful expansion and 
establishment of pure ECFC cultures. This was evident from our inability to successfully isolate 
and establish ECFC cultures from lungs of term rat fetuses. Secondly, it was more difficult to 
establish pure ECFC cultures from rat lungs compared to human. Greater numbers of 
contaminating cells, due to non-specific binding of rat anti-CD31, could possibly explain this 
difference. Finally, using this technique, we are able to obtain pure cultures of lung ECFCs by 
passage 4 or above. Differences in functional properties of ECFCs due to experimental or 
clinical disease processes may be lost is cells are passaged many times and this will need to be 





• DMEM, high glucose 1x (GIBCO-Invitrogen, cat. no. 11965) 
• Antibiotic-antimycotic: Penicillin (10 000 U/mL)/streptomycin (10 000 
μg/mL)/amphotericin (25 μg/mL) (PSA [100x]) (Invitrogen, cat. no. 15240) 
• Human lung tissue sample (e.g., we typically use human embryonic lung samples of 15-
18 week gestational age, stored in DMEM with 2% antibiotic-antimycotic)  or freshly 
isolated rat lung tissue. Caution: Experiments involving human tissue require informed 
consent to have been obtained.  Experiments involving human or rats must conform to 
National and Institutional regulations.  All procedures described here were approved by 
the Animal Health Care Committee of the University of Alberta. Human lung tissue 
collection was reviewed and approved by the Institutional Review Board at the 
University of New Mexico. 
• Dulbecco’s phosphate buffered saline (PBS), without calcium and magnesium, pH 7.2 
(Sigma, cat. no. D8537) 
• Trypan blue solution 0.4% (GIBCO-Invitrogen, cat. no. 15250-061) 
• Endothelial basal medium (EBM)-2 (Lonza, cat. no. cc-3156) 
• EGM-2 growth factor supplement singlequots (Lonza, cat. no. cc-4176) 
• Trypsin-EDTA (0.25%) (Invitrogen, cat. no. 25200) 
• Collagen Type I solution (BD Biosciences, cat. no. 354236) 
• Fetal bovine serum (FBS; Sigma Life Science, cat. no. F1051-100 mL) 
• Collagenase/dispase (Roche Diagnostics, cat. no. 11097 113001) 
• Streptavidin tagged M-280 dynabeads (Dynal, cat. no. 112.05D) 
• Biotinylatyed anti-CD31 antibody (human- Abcam, cat. no. ab7385; rat- BD Pharmingen, 
cat. no. 555026) 
• Bovine serum albumin (Sigma, cat. no. A7906) 
• Glacial acetic acid (17.4 N) (Fisher Scientific, cat. no. 505216) 
• 70% ethanol 
• Vacuum grease, sterilized (Dow Corning, cat. no. 1658832) 
• Dimethyl sulphoxide (DMSO), sterile filtered (Sigma, cat. no. D2650) 
 
Equipment: 
• 6-, 24- and 96-well plates (BD Biosciences Falcon) 
• 25 and 75 cm2 vented tissue culture flasks (BD Biosciences Falcon) 
• 15 mL and 50 mL conical centrifuge tubes (BD Biosciences Falcon) 
• 10 cm petri dish, sterile (Coning, cat. no. 430167) 
• 1 mL, 10 mL syringes, sterile (BD Biosciences, cat. nos. 309602 & 301604) 
• Blades, sterile & disposable 
• Pasteur pipettes (VWR, 14673-043), sterilized 
• Round bottomed polystyrene culture tubes (12 mm x 75 mm H) (BD Biosciences Falcon, 
cat. no. T405-3) 
• Cryovials (Nunc, cat. no. 375418) 
• Anatomical scissors, tweezers 
• Mcllwain tissue chopper (Brinkmann, Westbury, NY, USA) 
• Cell strainers, nylon (Fisher Scientific; cat. no. 22363547 [40 μm], 22363548 [70 μm]) 
• 0.22 μm vacuum filtration system (Millipore, cat. no. SCGPU05RE) 
• Neubauer chamber (Reichert, Buffalo, N.Y.) 
• Magnet (Dynal MPC-STM/MPC-LTM or DynaMagTM -2/-15) 
• Assorted pipettes (2-20 μL, 20-200 μL, 100-1000 μL) with sterile, disposable tips 
• Centrifuge 
• 37oC cell culture incubator 
• 37oC water bath 
• Inverted microscope 
• Fine tipped marker 
• Aluminium foil 
• Glass dish 





Dissolve Dulbecco’s PBS with 0.1% (w/v) bovine serum albumin. Can be stored up to 2 weeks 
at 4oC 
 
Serum-free ‘basal’ DMEM (basal-DMEM) 
DMEM + 1% (v/v) PSA. Can be stored in 4oC for up to 2 months. 
 
10% FBS ‘complete’ DMEM (complete-DMEM)  
DMEM + 10% (v/v) fetal bovine serum + 1% (v/v) PSA. Can be stored in 4oC for up to 2 
months. 
 
Complete EGM-2 (cEGM-2) 
Supplement EBM-2 with all components of EGM-2 growth factor bullet-kit except human 
epidermal growth factor (hEGF), 10% (v/v) fetal bovine serum and 1% (v/v) PSA. Store up to 1 
month at 4oC. 
 
Collagenase/dispase digestive solution 
Make up 5X stock solution by dissolving 5 mg of lyophilized collagenase/dispase ( 0.1 U 
collagenase & 0.8 U dipase/mg lyophilizate)  per mL double distilled (dd)-water. Store at -20oC 
up to one month. On the day of experiment, dilute 5X stock 5 times with Dulbecco’s PBS. 
Critical: Prepare working dilution on the day of the experiment. 
 
Collagen type I solution 
Dilute 0.575 mL of glacial acetic acid (17.4 N) in 495 mL dd-water (final concentration, 0.02 N) 
and sterile filtere with 0.22 μm vacuum filtration system. Dilute Collagen type I stock with 0.02 
N acetic acid to yield 50 μg/mL working dilution. The volume of collagen to use will vary 
depending on the supplied collagen stock concentration. Store up to 1 week at 4oC. 
 
Sterile vacuum grease 
Spread a small amount of vacuum grease into a thin layer in an autoclavable glass dish. After 
setting the lid, wrap the glass dish in aluminium foil, autoclave and cool completely.  
 
Coating of cell culture surfaces with collagen type I.  Add the working dilution (50 μg/mL) of 
collagen type I solution to the surface to be coated.  Use 1ml for each well of a six well plate, 
300 μL/well for 24 well plates, 2-3 mL/25-cm2 flask and 5-6 mL/75-cm2 flask.  Incubate 90 min 





Critical: Work in strictly aseptic conditions (preferably under the cell culture hood) at all times 
 
Preparation of reagents 
1. Prepare two to three 15 or 50 mL centrifuge tubes with fresh DMEM + 1% (v/v) 
antibiotic/anti-fungal solution and place over ice (4oC), ready to use. 
2. Preheat the incubator to 37oC. 
 
 
Preparation of anti-CD31 tagged magnetic beads 
3. Take 1 mg (100 μL of supplied suspension) of streptavidin tagged M-280 dynabeads in a 
1.8 mL cryovial. 
4. Add 500 μL MACS buffer and mix well. 
5. Place the cryovial in the magnet for 1 min and pipette off supernatant completely. 
6. Remove the cryovial from the magnet and resuspend the washed dynabeads with 500 μL 
MACS buffer.  
7. Repeat steps 5 and 6 two more times 
8. At the end of the third wash, resuspend the dynabeads in MACS buffer and add 10 μg of 
biotinylated anti-CD31 antibody while mixing, to reach an overall volume of 100 μL 
Critical Step: The volume of antibody solution containing 10 μg of antibody varies depending on 
the supplied concentration. Add appropriate volume of antibody solution first and then make it 
up to 100 μL by adding MACS buffer. 
9. Incubate for 30 min at room temperature (RT; 18-25oC) with gentle tilting and rotation. 
10. Add 500 μL MACS buffer and pipette up and down several times. 
11. Wash dynabeads three times as described in steps 5 and 6. 
12. Resuspend dynabeads in 100 μL MACS buffer. Leave on ice (4oC) until use. 
PAUSEPOINT: Anti-CD31 tagged magnetic beads can be prepared as described above, 1 day 
before the experiment and stored at 4oC until use. This reduces effort on the day of the 
experiment, especially if performing this protocol for the first time. 
 
Preparation of lung samples 
13. If isolating human cells, follow option A.  If isolating rat cells, follow option B. 
A) Human cells. 
i) Collect fetal or adult biopsied/autopsied lung samples into 15 or 50 mL centrifuge 
tubes with basal DMEM (prepared in step 1) and immediately store on ice   
PAUSEPOINT: Biopsies can be stored on ice for up to 24 hrs. 
 
The lung samples should ideally be processed for ECFC isolation, the same day. In some 
circumstances, immediate processing may not be possible, if for example, lungs are shipped from 
another centre. In this case, carefully store lungs at 4oC in basal DMEM for not more than 24 hrs. 
In the authors' experience, ECFC colonies can be isolated following this holding period; 
however, the number of colonies will decrease as the time between sample collection and 
processing increases.  Samples should not be allowed to freeze at any time during shipment. 
  
 
B) Rat cells. 
i) Sacrifice the rat using sodium phenobarbitol  (65 mg/kg, i.p.). 
ii) Wet the chest of the rat with 70% ethanol and open the chest of the rat with anatomical 
scissors. 
iii) Remove whole lungs of the rat with anatomical scissors and tweezers. 
iv) Transfer the lungs into 15 or 50 mL centrifuge tubes with basal DMEM (prepared in 
step 1) and immediately store on ice. 
 
Isolation of Total Lung Cells 
14. Transfer lungs from the centrifuge tubes into a Petri dish. 
15. Wash whole lungs with serum-free basal DMEM 
16. If using rat tissue, slice the peripheries of lung lobes, discarding the contents of the hilum 
and the proximal alveolar tissue. Remove thin strips of alveolar tissue subjacent to the 
pleural surface. Alternatively, for the human lung, trace the pleural surface of the 
supplied lung piece and remove strips of tissue immediately underlying the pleural 
surface.  
17. Add a few drops of basal-DMEM and chop the lung tissue using sterile, disposable 
blades to very small pieces (approximately 1-2 mm2) that could be drawn into a 5 mL 
pipette. 
18. Transfer the pieces into a 15 mL centrifuge tube containing 1x working dilution of 
collagenase/dispase digestive solution (7-10 mL per 0.5 g wet tissue). 
19. Digest the lung at 37oC for 45 min under continuous horizontal shaking (300 r.p.m.). 
20. Quench the lung-digestive solution mixture with equal volume of complete-DMEM  
21. Draw the mixture up and down several times using a 5 mL pipette. 
22. Place 70 μm cell strainer on a 50 mL tube 
23. Under sterile conditions, strain the lung digest through the 70 mm cell strainers by 
releasing the lung digest on the cell strainer using a 5 mL pipette. 
Caution: Slowly release the lung digest on the strainer to avoid overflowing of digested 
suspension. More than one 70 mm cell strainers may be needed at this step.  
24. Wash the cell strainer with 2-3 mL of complete-DMEM 
25. Re-strain the cell suspension through a 40 μm cell strainer into a 50 mL centrifuge tube 
26. Centrifuge the 50 mL tube at 300 g at 4oC for 10 min. 
27. Decant the supernatant and resuspend the cell pellet in 10 mL of complete-DMEM. 
28. Centrifuge the 50 mL tube at 300 g at 4oC for 10 min. 
29. Decant the supernatant and resuspend the cell pellet in 5 mL of MACS buffer. 
TROUBLESHOOTING:  
Magnetic selection of CD31+ cells 
30. Determine cell number of each sample of total lung cells using a modified Neubauer 
chamber. Prepare 1:10 and 1:100 dilutions of each sample in addition to the undiluted 
suspension. Mix 10 μL of these dilutions in a 1:1 ratio with trypan blue and count cells. 
31. Centrifuge the unstained cell suspension at 300 g for 10 min. 
32. Decant the supernatant and resuspend the cell pellet in 1 mL of MACS buffer per 107 
total cells. Strain the cell suspension through a 40 μm cell strainer to remove any cell 
aggregates. 
33. Add 25 μL dynabeads per 107 total cells.  
Caution: The volumes used above for magnetic selection are for up to 107 total cells. When 
working with fewer than 107 cells, use the same volumes as indicated. If a sample contains more 
than 107 cells, scale up all reagent and total volumes accordingly.  
34. Incubate for 30 min at 2-8oC with gentle tilting and rotation. 
Critical Step: Use a mixer that provides tilting and rotation of the tubes to ensure dynabeads do 
not settle at the bottom of the tube. Strictly adhere to the incubation time and temperature to 
reduce phagocytic activity and other metabolic processes and to avoid lower purity or viability 
of the isolated cells. 
35. Double the cell suspension volume with MACS buffer to limit trapping of unbound cells.  
36. Place the tube in a magnet in aseptic conditions for 2 min. 
37. Discard the supernatant and gently wash the bead-bound cells with 1 mL MACS buffer. 
38. Place the tube in the magnet for 1 min and discard the supernatant. 
39. Repeat steps 37 and 38 four times. At the end, add enough MACS buffer to thoroughly 
resuspend all cells that would have adhered to the walls of the tube. Centrifuge the cell 
suspension at 300 g for 10 min. Aspirate the supernatant. 
40. Resuspend cells in cEGM-2 to obtain a suspension of 7.5x104 to 1.0x105 cells/mL. 
TROUBLESHOOTING:  
 
Plating of CD31+ cells in culture 
41. Remove the rat tail collagen type I solution from a collagen-coated 6-well tissue culture 
plate and wash the surface twice with PBS (using 2 mL PBS per well).  Critical step : 
This step must be done immediately prior to plating the well plate with cells. 
 
42. Pipette 2 mL (approx. 4000-5000 cells) into each well of the 6 well plate precoated with 
rat tail collagen type I and place in a 37oC, 5% CO2 humidified incubator. 
43. After 24 hr (day 1), slowly remove the medium from the well with a pipette. 
Critical step: Aspirate medium slowly at a rate of 1 mL per 4-5 sec. A small quantity of medium 
should be left behind in the well to prevent drying of the plate surface. 
44. Slowly add 2 mL of cEGM-2 to the well. Return the plates to the incubator. 
45. Refresh the medium daily (as described in steps 43 and 44) until day 7 and every other 
day thereafter. ECFC colonies should appear between day 4 and day 14 of culture as well 
circumscribed areas of cobblestone-appearing cells (Figure 3 and 4A, white arrows). 
Individual colonies should be isolated and expanded as described in the following steps 
between days 7 to day 14. Mesenchymal stem cells (MSC)-like contaminating cells 
appear as dendritic/fibroblast-like cells (Figure 3 and 4A, white arrowhead and 4B and C) 
that can overgrow ECFC. 
Critical Step: ECFC colony isolation should be done very soon after contaminating cells are 
seen, to ensure a pure subculture of ECFC.  
 
ECFC colony isolation 
46. Visualize the ECFC colonies using an inverted microscope and outline the colony 
boundaries with a fine tipped marker on the underside of the well.  
47. Using sterile forceps pick a cloning cylinder from its packing and dip the bottom surface 
into autoclaved vacuum grease to acquire a uniform coating. 
Critical Step: Always apply the minimum amount of vacuum grease necessary to uniformly coat 
the bottom surface of the cloning cylinder and form a good seal with the culture plate. Too much 
grease will interfere with cell collection. Prepare cloning cylinders just prior to use. 
48. Aspirate the culture medium and wash the well with 2-3 mL PBS. 
49. After aspirating the PBS, set a clonal ring around each colony and press firmly against 
the plate with forceps. 
Caution: Carefully apply vertical pressure to seal the cloning cylinder against the culture plate. 
Avoid any inadvertent sliding of the cylinder as this can disrupt the ECFC colony. 
50. Using a 20-200 μL pipette, add 50-150 μL of warm trypsin/EDTA into each cloning 
cylinder. 
Critical Step:  Make sure that sufficient quantity of trypsin/EDTA is added to cover the entire 
area within the cloning cylinder. 
51. Incubate plates up to 5 min until the cells have completely detached. 
52. Draw 200 μL of cEGM-2 into a 20-200 μL pipette. 
53. When all cells within the cloning cylinder have detached, place the tip of the pipette into 
the center of the cylinder and pipette up and down several times.  
54. Collect the entire volume into a sterile microcentrifuge tube containing an equal volume 
of cEGM-2 and mix well. 
55. Wash the area within the cloning cylinder 1-2 times with 200 μL cEGM-2 and transfer 
washes into the sterile microcentrifuge tube until all detached cells are collected into the 
microcentrifuge tube. 
56. Remove the rat tail collagen type I solution from a collagen-coated 24-well tissue culture 
plate and wash the surface twice with PBS (using 1 mL PBS per well).  Critical step : 
This step must be done immediately prior to plating the well plate with cells. 
57. Seed the cells from each ECFC colony into one well of the 24-well cell culture plate 
precoated with rat tail type-I collagen in a total volume of 1 mL of cEGM-2 and culture 
in a 37oC, 5% CO2 humidified incubator for expansion 
Critical Step: If the ECFC colony is small (fewer than 100 cells), cells from 2-3 colonies can be 
pooled and plated into one well of a 24-well cell culture plate.   
TROUBLESHOOTING:  
 
Further Purification and Expansion of ECFC 
58. When cells in the 24-well plate approach confluence, remove cell culture medium and 
wash the culture surface with PBS. 
59. After removal of PBS, add 100 μL of trypsin/EDTA per well of the 24-well plate and 
incubate plates up to 5 min until the cells have completely detached. 
60. Pipette up and down thoroughly with 500 μL of cEGM-2 to collect the detached cells into 
a 15 mL centrifuge tube. 
61. Wash the well 1-2 times with 500 μL cEGM-2 until all detached cells are collected into 
the centrifuge tube. 
Critical Step: Cells from up to 2-3 confluent wells can be pooled into one centrifuge tube. 
62. Make the volume of the cell suspension up to 12-14 mL with cEGM-2 and mix well by 
pipetting up and down gently. 
63. Remove the rat tail collagen type I solution from a collagen-coated 75 cm2 vented tissue 
culture flask and wash the surface twice with PBS (using 10 mL PBS per well).  Critical 
step : This step must be done immediately prior to plating the well plate with cells. 
64. Plate the cells in the 75 cm2 vented tissue culture flask precoated with rat tail type-I 
collagen and culture in a 37oC, 5% CO2 humidified incubator for expansion. 
65. Replace culture medium with fresh cEGM-2 every other day and culture until cells 
approach 80-90% confluence. 
Critical Step: Cultures should reach 80-90% confluence in 4-7 days. 
TROUBLESHOOTING:  
 
66. When the tissue culture flasks have approached 80-90% confluence, carefully examine 
the cultured cells using inverted microscope to spot areas of MSC-like contaminating cell 
colonies as opposed to uniform cobblestone-appearing ECFC monolayer.  
Critical Step: It is not uncommon to find MSC-like contaminating cell colonies interspersed with 
the ECFCs in early passages of the culture. The contaminating cells appear as described under 
step 47. The ECFCs can be purified further by performing approximately 3-5 cycles of CD31-
positive magnetic selection and subculturing, as described in steps 67-75. 
67. Remove culture medium from the cell culture flasks and wash the culture surface 
liberally with PBS. 
Critical Step: For a 75 cm2 tissue culture flask, use 8-10 mL of PBS for the washes. 
 
68. Aspirate PBS and add 3 mL trypsin/EDTA per 75 cm2 culture flask. 
Critical Step: Warm trypsin/EDTA to 37oC prior to use. . 
69. Incubate the flask at 37oC until the cells detach completely. 
TROUBLESHOOTING:  
 
70. Add 8-10 mL of cEGM-2 and collect the cells completely into a 15 mL centrifuge tube. 
71. Centrifuge the 15 mL tube at 300 g at 4oC for 5 min. 
72. Decant the supernatant and resuspend the cell pellet in 1 mL of MACS buffer. 
73. Take up 10 μL of the ECFC suspension and mix with 10 μL trypan blue. 
74. Apply 10 μL of this mixture into a modified Neubauer chamber and count the cells 
Critical Step: Usually a confluent 75 cm2 tissue culture flask contains 2-4 million ECFCs. Up to 
107 cells can be suspended in 1 mL of MACS buffer.  
75. Perform a MACS selection of CD31 positive cells following the procedure described in 
steps 31-40. 
Critical Step: This step is to remove the MSC-like contaminating cells (Figure 4) and to obtain a 
pure culture of ECFCs. If contaminating cells are still present upon further passage, repeat 
MACS selection of CD31 positive cells at each passage until a pure ECFC culture is obtained. 
Fluorescence activated cell sorting (FACS)-based selection for CD31+ cells may also be 
considered at this step. Usually pure ECFC cultures are obtained after 2-4 cycles of CD31-
positive selection performed over 2-4 passages. 
Troubleshooting  
See Table 1 for Troubleshooting guidance. 
 
Timing 
Isolation of CD31+ cells from lung samples and their initial plating in culture (steps 1-40) 
requires ~4.5 hrs. The approximate timeline for the different steps this involves are as follows: 
• Preparation of reagents: 2 hrs (Steps 1-12) 
• Remove lungs from rat: 5 min  (Step 13) 
• Isolation of total lung cells: 1 hr 45 min (Steps14-29) 
• Magnetic selection: 30 min (Steps31-40) 
Late-outgrowth ECFC colonies usually arise in culture of CD31+ lung cells between days 4 and 
14. These colonies can be isolated and expanded in culture in two to three 75-cm2 flasks in ~2 
weeks for human lung samples and ~3 weeks for rat lungs (Steps 41-57). The expanded cells 
should be processed through 2-4 cycles of CD31+ selection done over 2-4 passages to obtain 
pure cultures. This may take an additional 2-3 weeks (Steps 58-75). There is variability in the 
number of primary ECFC colonies obtained and their population doubling times between donors 
for human lungs. For instance, we obtained approximately 20 ± 5 colonies/5000 CD31+ cells 
plated (mean ± SD from 4 independent trials). For rats, since routinely lung tissue is pooled from 
several animals, not much variability is observed. Here, approximately 40 ± 5 ECFC colonies 
were obtained by plating 5000 CD31+ cells (data from 5 independent trials). 
Anticipated Results 
 
Initiation and propagation of ECFCs 
ECFC colonies appear between 7 and 14 days of culture. Routinely, embryonic human lung 
samples can be expanded to 107 cells in 5-6 weeks. Rat lungs, on the other hand, may require a 
longer time (6-8 weeks) to yield the same number of ECFCs. Both rat and human lung vascular 
ECFCs have the potential to be cultured for up to 15 passages before they start expressing 
morphological indications of senescence such as slow multiplication and appearance of 
cytoplasmic vacuoles. These observations are consistent with previous studies on human adult 
EPCs15,18. 
 
Phenotypic characterization of lung vascular ECFCs 
Lung vascular ECFCs grow as a monolayer with the characteristic “cobblestone” morphology. 
They ingest AcLDL, bind Ulex lectin and form capillary tube-like networks when plated on 
Matrigel (Figure 5A). ECFCs uniformly express typical endothelial cell surface antigens CD31, 
CD146, CD105 and CD144, but do not express hematopoietic cell specific surface antigen CD45 
or monocyte/macrophage marker CD14 (see online supplement of reference17 for detailed 
methods) (Figure 5B). In addition, human lung ECFC are capable of giving rise to clusters (up 
to 50 cells) or colonies (50-500 cells or more than 500 cells) in 96-well plates where ECFCs are 
plated at a seeding density of 1 cell per well. In  three independent trials by the authors, 6.0 ± 1.2 
% and 7.5 ± 2.9 % (mean ± SD) of single plated human lung ECFCs formed colonies with 50-
500 cells and more than 500 cells, respectively (Figure 5C). This characteristic of “single-cell 
colony forming potential” is important in distinguishing ECFCs from mature endothelial cells13. 
The most stringent means to verify the functionality of ECFCs is to assess their ability to 
contribute to de novo vasculogenesis. In order to assess this property, ECFCs are loaded on 
collagen-fibronectin matrices and implanted subcutaneously in NOD/SCID mice. Cellularized 
collagen-fibronectin implants are excised after 14 days post-implantation and examined for 
vascularization by immunohistochemical staining. RBC perfused anti-human CD31+ vessels are 
identified in implants loaded with human lung ECFCs (Figure 6).  
Rat lung ECFCs isolated by this protocol also demonstrate all the defining characteristics of 
ECFCs, as shown in Alphonse et al17. Rat ECFCs express endothelial surface markers VCAM-1 
and ICAM-215,24. They also express CD34 and c-Kit, cell-surface antigens previously identified 
on endothelial and hematopoietic progenitor cells15,25 (Figure 7). In addition to binding Ulex 
europaeus lectin, rat lung ECFCs also bind the lectin from Griffonia simplicifolia, indicating its 
likely origin from lung microvasculature26.  
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Table 1 Troubleshooting Guide 
 
Step Problem Possible Reason Solution 
29 Too few viable cells after 
enzymatic disintegration 
Poor storage conditions or 
prolonged storage of lung 
samples 
For rat lung, it is best to process them 
immediately after excision. For human 
lung, if immediate processing is not 
feasible or if being shipped from 
another centre, carefully store at 4oC in 
basal DMEM for not more than 24 hrs. 
Samples should never be allowed to 
freeze anywhere during this storage 
period. 
  Too long or too vigorous 
shaking during enzymatic 
digestion step 
Do not leave the chopped lung sample 
for more than 45 min in pre-warmed 
collagenase/dispase. Do not shake at 
speeds greater than 300 r.p.m. 
40 Too few viable cells after 
CD31+ MACS selection 
Miscalculation during anti-
CD31 tagging of dynabeads 
Recheck the amount of anti-CD31 
antibody added per unit volume of 
dynabeads 
  Miscalculation during 
coating of cells with anti-
CD31 tagged dynabeads 
Recheck the amount of anti-CD31 
tagged dynabeads added per 107 cells  
  Incubation temperature too 
high or too low 
Strictly adhere to the incubation time 
and temperature specified in the 
protocol 
57 No ECFC colonies appear Harsh treatment of plated 
CD31+ cells 
Remove and replace medium very 
slowly and gently during the first week 
of culture. Do not use vacuum suction 
to remove medium. 
  Very low CD31+ cell 
seeding density 
Plate at least 3-5 x 103 CD31+ 
cells/well at step 42. 
  Insufficient enzyme 
digestion 
Make sure the tissue is chopped 
adequately (to obtain 1-2 mm3 pieces). 
Also make sure there is sufficient 
enzyme added to the chopped tissue 
(~ 10 mL of enzyme solution [working 
dilution] per 0.5 g tissue) 
  Insufficient washing of cells 
(with beads attached) 
In steps 37 and 38, make sure the 
cells (with attached beads) are washed 
sufficiently and properly suspended in 
MACS buffer to minimize CD31+ cell 
loss 
57 Too many contaminating 
cells around ECFC colonies 
(Figure 4) 
Antibody problem Antibodies may not be very specific. 
Use antibodies from standard 
manufacturers, preferably the same 
ones used in this protocol. Do not 
subject antibodies to repeated freeze-
thaw cycles and leave on ice all the 
Step Problem Possible Reason Solution 
time before use.  
  Ineffective coating of cells 
with anti-CD31 tagged 
dynabeads 
Strictly adhere to the incubation time 
and temperature specified in the 
protocol.  High phagocytic activity will 
result in non-CD31+ cells being 
selected out in large numbers. 
  Improper timing for ECFC 
colony selection 
ECFC colonies generally appear 
anytime between 4 and 14 days of 
culture. If colonies are not selected 
promptly after appearance of ECFC 
colonies, MSC-like contaminating cells 
will quickly overgrow the cultures. 
65 Insufficient purity of yields Overgrowth of 
contaminating cells over 
time 
Positive selection for CD31+ cells via 
MACS or FACS over 2-4 passages will 
yield clean ECFC cultures.  
  Contaminating cells picked 
up along with ECFC 
colonies 
After circling ECFC colonies with a 
marker pen, scratch out any 
contaminating cells around the 
colonies with a pipette tip. Select the 
size of the cloning cylinders to be just 
enough to cover the colonies. 
65 ECFCs do not attach and 
grow 
Ineffective type I collagen 
coating of culture surfaces 
If plated on uncoated culture surfaces, 
ECFCs never attach and grow. Use 
fresh and properly constituted type I 
collagen solution for coating. If expired 
collagen stock or improperly 
constituted working dilutions are used, 
ECFCs may fail to attach and grow. 
65 ECFCs are not dividing Cells are senescent ECFC-derived mature endothelial cells 
eventually undergo senescence. For 
best results in functional assays, use 
ECFCs between passages 5 and 10.  
69 ECFCs do not detach Serum may block trypsin 
activity 
Wash 2-3 times with PBS to remove 
leftover serum components, prior to 
adding trypsin. 
  Trypsin activity is low Use fresh, warm trypsin. Freeze 
trypsin in smaller aliquots so that once 
thawed, the entire aliquot is used and 





Figure 1. Flow diagram of the steps involved in lung ECFC isolation. 
 
Figure 2. Schematic representation of lung dissection and lung cell suspension preparation 
(protocol steps 14 to 29). After thoracotomy and careful excision of the rat lung, the peripheral 
rims of all lung lobes are dissected. The lung tissue is chopped into approximately 1-2 mm2 
pieces and dispersed into a single cell suspension by incubation in collagenase/dispase digestion 
solution. 
 
Figure 3. Schematic representation of CD31+ cell selection, plating and ECFC colony 
isolation (protocol steps 30 to 57). CD31+ cells are selected from the total lung cell suspension 
using magnetic-activated cell sorting (MACS). CD31+ lung cells are plate and cultured in type I 
collagen-coated 6 well plates containing complete-Endothelial Growth Medium-2 (cEGM-2). 
Late-outgrowth 'cobblestone-like' ECFC colonies appear between 4-14 days. The individual 
ECFC colonies are carefully marked and isolated using cloning cylinders. ECFCs are expanded 
in cEGM-2 culture and purified with 2-4 cycles of CD31+ selection and passaging. Scale bars in 
the microscopy images of ECFC colonies represent 100 μm.  
Figure 4. Representative photomicrographs of contaminating cells in ECFC culture. (A) 
Contaminating cells with mesenchymal stromal cell (MSC)-like or fibroblast-like phenotype 
(white arrowheads) are seen around a cobblestone-like rat lung ECFC colony (white arrow) 
using phase contrast microscopy (B) Contaminating cell cluster with fibroblast-like phenotype 
observed in passage 2 rat lung ECFC culture. (C) Contaminating cell colony observed in passage 
2 human lung ECFC culture. The scale bar in the images represents 100 μm. All procedures were 
approved by the Animal Health Care Committee of the University of Alberta. 
 
Figure 5. Representative phenotypic analysis of human lung vascular ECFCs. (A) Human 
lung ECFCs form cobblestone-like colonies when cultured as a monolayer. Cells are observed by 
phase contrast microscopy. Cultured ECFCs demonstrate Dil-acLDL uptake and Ulex 
europaeus-lectin binding. The cells ingest Dil-AcLDL (red) following 4 hrs of incubation and 
bind Ulex europaeus-lectin (green) following 1 hr of incubation after fixation. Counterstaining 
with Heochst 33258 (blue) illustrates that all adherent cells are positive for LDL-uptake and 
Ulex-lectin binding. It was observed that a modest number of stray MSC-like contaminating cells 
did not take up LDL. But these cells were totally lost following 2-4 cycles of CD31-positive 
selection and passaging. ECFCs formed tube-like structures when suspended in matrigel and 
observed by light microscopy. (B) Human lung ECFCs were positive for endothelial-specific cell 
surface antigens CD31, M-CAM (CD146), VE-cadherin (CD144), endoglin (CD105) and 
negative for hematopoietic cell specific CD45 and monocyte/macrophage specific CD14. Filled 
grey histograms represent antigen staining with negative isotype controls overlaid in white. (C) 
Human lung ECFC were capable of giving rise to clusters (2 to 50 cells) or colonies (51-500 
cells or 501 and above cells/colony) in 96-well plates, when ECFCs were plated at a seeding 
density of 1 cell per well. Results represent the average ± standard error of mean of 3 
independent experiments.  The y axis represents percentage of plated single cells. Human lung 
tissue collection was reviewed and approved by the Institutional Review Board at the University 
of New Mexico. Specific details about the methods used for phenotypic analysis are available in 
our earlier report17 and information about the antibodies used for cell labeling are provided in the 
supplementary information. 
 
Figure 6. Human lung ECFCs contribute to de novo vasculogenesis. Human lung ECFCs 
form blood vessels de novo when seeded on fibronectin-collagen plugs (106 ECFCs per implant) 
and implanted subcutaneously into the flanks of NOD/SCID mice. 7 days post implantation, the 
cellularized implants were excised, paraffin embedded and stained with hematoxylin and eosin 
(H&E) and anti-human CD31 (brown). Black arrow heads indicate red blood cell (RBC)-
perfused, anti-human CD31+ vessels within the gel implant. Scale bars represent 65 μm. Human 
lung tissue collection was reviewed and approved by the Institutional Review Board at the 
University of New Mexico. 
 
Figure 7. Surface antigen expression and lectin binding characteristics of rat lung vascular 
ECFCs. Rat lung ECFCs express the cell surface antigens CD34, ICAM-2, VCAM-1 (CD19) 
and c-Kit. Rat ECFCs bind lectins from Ulex europaeus and Griffonia simplicifolia following 1 
hr of incubation after fixation. Dark coloured histograms represent antigen staining with negative 
isotype controls overlaid in pale grey. Specific details about the antibodies used for cell staining 
have been provided in the supplementary information. The specificity of these antibodies is 







1 Murray, C. J. & Lopez, A. D. Alternative projections of mortality and disability by cause 
1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504, 
doi:10.1016/S0140-6736(96)07492-2 (1997). 
2 Liebow, A. A. Pulmonary emphysema with special reference to vascular changes. Am 
Rev Respir Dis 80, 67-93 (1959). 
3 Sluiter, I. et al. Vascular abnormalities in human newborns with pulmonary hypertension. 
Expert Rev Respir Med 5, 245-256, doi:10.1586/ers.11.8 (2011). 
4 Thebaud, B. & Abman, S. H. Bronchopulmonary dysplasia: where have all the vessels 
gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care 
Med 175, 978-985, doi:10.1164/rccm.200611-1660PP (2007). 
5 Voelkel, N. F., Douglas, I. S. & Nicolls, M. Angiogenesis in chronic lung disease. Chest 
131, 874-879, doi:10.1378/chest.06-2453 (2007). 
6 Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. 
Science 275, 964-967 (1997). 
7 Asahara, T. Cell therapy and gene therapy using endothelial progenitor cells for vascular 
regeneration. Handb Exp Pharmacol, 181-194, doi:10.1007/978-3-540-68976-8_8 
(2007). 
8 Khoo, C. P., Pozzilli, P. & Alison, M. R. Endothelial progenitor cells and their potential 
therapeutic applications. Regen Med 3, 863-876, doi:10.2217/17460751.3.6.863 (2008). 
9 Kirton, J. P. & Xu, Q. Endothelial precursors in vascular repair. Microvasc Res 79, 193-
199, doi:10.1016/j.mvr.2010.02.009 (2010). 
10 Steinmetz, M., Nickenig, G. & Werner, N. Endothelial-regenerating cells: an expanding 
universe. Hypertension 55, 593-599, doi:10.1161/HYPERTENSIONAHA.109.134213 
(2010). 
11 Borghesi, A. et al. Circulating endothelial progenitor cells and diseases of the preterm 
infant. Minerva Pediatr 62, 21-23 (2010). 
12 Huertas, A. & Palange, P. Circulating endothelial progenitor cells and chronic pulmonary 
diseases. Eur Respir J 37, 426-431, doi:10.1183/09031936.00034810 (2011). 
13 Ingram, D. A. et al. Identification of a novel hierarchy of endothelial progenitor cells using 
human peripheral and umbilical cord blood. Blood 104, 2752-2760, doi:10.1182/blood-
2004-04-1396 (2004). 
14 Yoder, M. C. Is endothelium the origin of endothelial progenitor cells? Arterioscler 
Thromb Vasc Biol 30, 1094-1103, doi:10.1161/ATVBAHA.109.191635 (2010). 
15 Ingram, D. A. et al. Vessel wall-derived endothelial cells rapidly proliferate because they 
contain a complete hierarchy of endothelial progenitor cells. Blood 105, 2783-2786, 
doi:10.1182/blood-2004-08-3057 (2005). 
16 Prater, D. N., Case, J., Ingram, D. A. & Yoder, M. C. Working hypothesis to redefine 
endothelial progenitor cells. Leukemia 21, 1141-1149, doi:10.1038/sj.leu.2404676 
(2007). 
17 Alphonse, R. S. et al. Existence, functional impairment, and lung repair potential of 
endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 
129, 2144-2157, doi:10.1161/CIRCULATIONAHA.114.009124 (2014). 
18 Mead, L. E., Prater, D., Yoder, M. C. & Ingram, D. A. Isolation and characterization of 
endothelial progenitor cells from human blood. Curr Protoc Stem Cell Biol Chapter 2, 
Unit 2C 1, doi:10.1002/9780470151808.sc02c01s6 (2008). 
19 King, J. et al. Structural and functional characteristics of lung macro- and microvascular 
endothelial cell phenotypes. Microvasc Res 67, 139-151, doi:10.1016/j.mvr.2003.11.006 
(2004). 
20 Alvarez, D. F. et al. Lung microvascular endothelium is enriched with progenitor cells 
that exhibit vasculogenic capacity. Am J Physiol Lung Cell Mol Physiol 294, L419-430, 
doi:10.1152/ajplung.00314.2007 (2008). 
21 Schniedermann, J. et al. Mouse lung contains endothelial progenitors with high capacity 
to form blood and lymphatic vessels. BMC Cell Biol 11, 50, doi:10.1186/1471-2121-11-
50 (2010). 
22 May, T. et al. Establishment of murine cell lines by constitutive and conditional 
immortalization. J Biotechnol 120, 99-110, doi:10.1016/j.jbiotec.2005.03.027 (2005). 
23 Rafii, S. et al. Isolation and characterization of human bone marrow microvascular 
endothelial cells: hematopoietic progenitor cell adhesion. Blood 84, 10-19 (1994). 
24 de Fougerolles, A. R., Stacker, S. A., Schwarting, R. & Springer, T. A. Characterization 
of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med 174, 253-267 
(1991). 
25 Fang, S., Wei, J., Pentinmikko, N., Leinonen, H. & Salven, P. Generation of functional 
blood vessels from a single c-kit+ adult vascular endothelial stem cell. PLoS Biol 10, 
e1001407, doi:10.1371/journal.pbio.1001407 (2012). 
26 Wu, S., Zhou, C., King, J. A. & Stevens, T. A unique pulmonary microvascular 
endothelial cell niche revealed by Weibel-Palade bodies and Griffonia simplicifolia. Pulm 





The isolation and culture of endothelial colony forming cells from human and rat lungs   
 
Rajesh S Alphonse, MBBS, MMST, PhD1, Arul Vadivel, PhD2, Shumei Zhong, MSc2, Suzanne 
McConaghy3, Robin Ohls3, MD, Mervin C Yoder, MD4, and Bernard Thébaud, MD, PhD2 
 
1Department of Pediatrics and Women and Children Health Research Institute, University of 
Alberta, Edmonton, AB, Canada; 2 Ottawa Hospital Research Institute, Regenerative Medicine 
Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children’s Hospital of 
Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada; 3 Department of Pediatrics, 
University of New Mexico, Albuquerque, New Mexico, USA; 4Wells Center for Pediatric 
Research, Indiana University School of Medicine, Indianapolis, IN, United States 
 
Correspondence:  
Dr. Bernard Thébaud MD, PhD 
Ottawa Hospital Research Institute 
Regenerative Medicine Program, The Ottawa Hospital 
501 Smyth Road, Ottawa (Canada) K1H 8L6  






Human ECFC Surface Marker Characterization 
Surface Marker Antibody Supplier Information 
CD31 Anti-human CD31 
antibody, FITC 
BD Pharmingen, Cat. No. 
555445 
CD45 Anti-human CD45 
antibody, FITC 
BD Pharmingen, Cat. No. 
555482 
CD14 Anti-human CD14 
antibody, FITC 
BD Pharmingen, Cat. No. 
555397 
CD144 (VE-Cadherin) Anti-human CD144 
antibody, PE 
eBioscience, Cat. No. 12-
1449-80 
CD146 (M-CAM) Anti-human CD146 
antibody, PE 
BD Pharmingen, Cat. No. 
550315 
CD105 (Endoglin) Anti-human CD105 
antibody, PE 
Invitrogen, Cat. No. 
MHCD10504 
 














Abcam, Cat. No.  
AB81289-2 







ICAM-2 ICAM-2 Antibody 
(H-159) 
Santa Cruz, Cat. 
No. sc-7933 







VCAM-1 VCAM-1 Antibody 
(C-19)-R 
Santa cruz, Cat. 
No. sc-1504-R 







c-Kit c-kit (2B8, biotin), 
rat monoclonal 
antibody 
Abcam, Cat. No. 
ab25022 
Streptavidin-Cy3 Sigma, Cat. No. 
s6402 
Ulex europaeus lectin, FITC 
conjugate 
Sigma,  Cat. 
No. L9006 
  
Griffonia simplicifolia lectin, TRITC  
conjugate 
Sigma, Cat. No. 
L5264 
  
 
 
